325 related articles for article (PubMed ID: 24680659)
1. Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib.
Miyake H; Nishikawa M; Tei H; Furukawa J; Harada K; Fujisawa M
Urol Oncol; 2014 Jul; 32(5):584-8. PubMed ID: 24680659
[TBL] [Abstract][Full Text] [Related]
2. Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array.
Perez-Gracia JL; Prior C; Guillén-Grima F; Segura V; Gonzalez A; Panizo A; Melero I; Grande-Pulido E; Gurpide A; Gil-Bazo I; Calvo A
Br J Cancer; 2009 Dec; 101(11):1876-83. PubMed ID: 19904265
[TBL] [Abstract][Full Text] [Related]
3. C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib.
Fujita T; Iwamura M; Ishii D; Tabata K; Matsumoto K; Yoshida K; Baba S
Int J Urol; 2012 Oct; 19(10):908-13. PubMed ID: 22671963
[TBL] [Abstract][Full Text] [Related]
4. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P
BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209
[TBL] [Abstract][Full Text] [Related]
6. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease.
Tayebjee MH; Lip GY; Tan KT; Patel JV; Hughes EA; MacFadyen RJ
Am J Cardiol; 2005 Aug; 96(3):339-45. PubMed ID: 16054454
[TBL] [Abstract][Full Text] [Related]
7. Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib.
Noé G; Bellesoeur A; Thomas-Schoemann A; Rangarajan S; Naji F; Puszkiel A; Huillard O; Saidu N; Golmard L; Alexandre J; Goldwasser F; Blanchet B; Vidal M
Oncotarget; 2016 Oct; 7(41):67507-67520. PubMed ID: 27589830
[TBL] [Abstract][Full Text] [Related]
8. Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma.
Kucharz J; Giza A; Dumnicka P; Kuzniewski M; Kusnierz-Cabala B; Bryniarski P; Herman R; Zygulska AL; Krzemieniecki K
Med Oncol; 2016 Oct; 33(10):109. PubMed ID: 27573381
[TBL] [Abstract][Full Text] [Related]
9. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients.
Porta C; Paglino C; Imarisio I; Ganini C; Sacchi L; Quaglini S; Giunta V; De Amici M
Oncology; 2013; 84(2):115-22. PubMed ID: 23154434
[TBL] [Abstract][Full Text] [Related]
10. The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib.
Basappa NS; Elson P; Golshayan AR; Wood L; Garcia JA; Dreicer R; Rini BI
Cancer; 2011 Mar; 117(6):1183-9. PubMed ID: 20960527
[TBL] [Abstract][Full Text] [Related]
11. Treatment-related deterioration of renal function is associated with the antitumor efficacy of sunitinib in patients with metastatic renal cell carcinoma.
Fukuda H; Kondo T; Iida S; Takagi T; Tanabe K
Urol Oncol; 2016 Aug; 34(8):338.e1-9. PubMed ID: 27085488
[TBL] [Abstract][Full Text] [Related]
12. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D
Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
14. Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma.
Voss MH; Chen D; Marker M; Hakimi AA; Lee CH; Hsieh JJ; Knox JJ; Voi M; Motzer RJ
Br J Cancer; 2016 Mar; 114(6):642-9. PubMed ID: 26908330
[TBL] [Abstract][Full Text] [Related]
15. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
Harmon CS; DePrimo SE; Figlin RA; Hudes GR; Hutson TE; Michaelson MD; Négrier S; Kim ST; Huang X; Williams JA; Eisen T; Motzer RJ
Cancer Chemother Pharmacol; 2014 Jan; 73(1):151-61. PubMed ID: 24220935
[TBL] [Abstract][Full Text] [Related]
16. Factors Prognostic for Survival in Japanese Patients Treated with Sunitinib as First-line Therapy for Metastatic Clear Cell Renal Cell Cancer.
Kawai Y; Osawa T; Kobayashi K; Inoue R; Yamamoto Y; Matsumoto H; Nagao K; Hara T; Sakano S; Nagamori S; Matsuyama H
Asian Pac J Cancer Prev; 2015; 16(14):5687-90. PubMed ID: 26320436
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
Ulrich D; Hrynyschyn K; Pallua N
Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
[TBL] [Abstract][Full Text] [Related]
18. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
Pilskog M; Beisland C; Akslen LA; Bostad L; Haug Å; Heinrich D; Hjelle KM; Straume O
BMC Urol; 2017 Aug; 17(1):74. PubMed ID: 28859644
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
